{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:45:29Z","timestamp":1773297929510,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1111\/ane.12839","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T09:50:37Z","timestamp":1508925037000},"page":"45-48","source":"Crossref","is-referenced-by-count":27,"special_numbering":"supplement S201","title":["Trials of antivirals in the treatment of multiple sclerosis"],"prefix":"10.1155","volume":"136","author":[{"given":"J.","family":"Lycke","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience; Institute of Neuroscience and Physiology at Sahlgrenska Academy; University of Gothenburg; Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,25]]},"reference":[{"key":"10.1111\/ane.12839-BIB0001|ane12839-cit-0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/ane.12839-BIB0002|ane12839-cit-0002","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/BOR.0b013e328362004d","article-title":"Multiple sclerosis: autoimmunity and viruses","volume":"25","author":"Cusick","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1111\/ane.12839-BIB0003|ane12839-cit-0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1212\/WNL.41.3.335","article-title":"Multiple sclerosis, retroviruses, and PCR. The HTLV-MS working group","volume":"41","author":"Ehrlich","year":"1991","journal-title":"Neurology"},{"key":"10.1111\/ane.12839-BIB0004|ane12839-cit-0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jns.2016.01.013","article-title":"Epstein-Barr virus and multiple sclerosis. From evidence to therapeutic strategies","volume":"361","author":"Fernandez-Menendez","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1111\/ane.12839-BIB0005|ane12839-cit-0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.coviro.2014.09.016","article-title":"Evidence linking HHV-6 with multiple sclerosis: an update","volume":"9","author":"Leibovitch","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1111\/ane.12839-BIB0006|ane12839-cit-0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12839-BIB0007|ane12839-cit-0007","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12839-BIB0008|ane12839-cit-0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.58.1.31","article-title":"A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS","volume":"58","author":"Bech","year":"2002","journal-title":"Neurology"},{"key":"10.1111\/ane.12839-BIB0009|ane12839-cit-0009","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","article-title":"A randomized clinical trial of valacyclovir in multiple sclerosis","volume":"11","author":"Friedman","year":"2005","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12839-BIB0010|ane12839-cit-0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF00868517","article-title":"Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study","volume":"243","author":"Lycke","year":"1996","journal-title":"J Neurol"},{"key":"10.1111\/ane.12839-BIB0011|ane12839-cit-0011","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1111\/ane.12839-BIB0012|ane12839-cit-0012","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jac\/24.6.947","article-title":"Acyclovir concentrations in serum and cerebrospinal fluid at steady state","volume":"24","author":"Lycke","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/ane.12839-BIB0013|ane12839-cit-0013","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1128\/AAC.47.8.2438-2441.2003","article-title":"Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir","volume":"47","author":"Lycke","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/ane.12839-BIB0014|ane12839-cit-0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2014-307932","article-title":"HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study","volume":"86","author":"Gold","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12839-BIB0015|ane12839-cit-0015","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/oxfordjournals.molbev.a004108","article-title":"Characterization of the intragenomic spread of the human endogenous retrovirus family HERV-W","volume":"19","author":"Costas","year":"2002","journal-title":"Mol Biol Evol"},{"key":"10.1111\/ane.12839-BIB0016|ane12839-cit-0016","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ng775","article-title":"Evidence for genomic rearrangements mediated by human endogenous retroviruses during primate evolution","volume":"29","author":"Hughes","year":"2001","journal-title":"Nat Genet"},{"key":"10.1111\/ane.12839-BIB0017|ane12839-cit-0017","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1073\/pnas.94.14.7583","article-title":"Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The collaborative research group on multiple sclerosis","volume":"94","author":"Perron","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/ane.12839-BIB0018|ane12839-cit-0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.msard.2016.04.006","article-title":"Human endogenous retrovirus W in brain lesions: rationale for targeted therapy in multiple sclerosis","volume":"8","author":"Horssen","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1111\/ane.12839-BIB0019|ane12839-cit-0019","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4161\/19420862.2014.985021","article-title":"Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein","volume":"7","author":"Curtin","year":"2015","journal-title":"MAbs"},{"key":"10.1111\/ane.12839-BIB0020|ane12839-cit-0020","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.clinthera.2012.11.006","article-title":"GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study","volume":"34","author":"Curtin","year":"2012","journal-title":"Clin Ther"},{"key":"10.1111\/ane.12839-BIB0021|ane12839-cit-0021","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1352458514554052","article-title":"A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients","volume":"21","author":"Derfuss","year":"2015","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12839-BIB0022|ane12839-cit-0022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2015.05.019","article-title":"A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up","volume":"285","author":"Derfuss","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1111\/ane.12839-BIB0023|ane12839-cit-0023","volume-title":"Phase 2 Baseline Versus Treatment Clinical Trial of the HIV Drug Raltegravir in Patients with Active Relapsing Remitting Multiple Sclerosis: The INSPIRE Study Results","author":"Marta","year":"2016"},{"key":"10.1111\/ane.12839-BIB0024|ane12839-cit-0024","volume-title":"Phase 2 Baseline Versus Treatment Clinical Trial of the HIV Drug Raltegravir in Patients with Active Relapsing Remitting Multiple Sclerosis: The INSPIRE Study Biomarker Outcome Results","author":"Gold","year":"2016"},{"key":"10.1111\/ane.12839-BIB0025|ane12839-cit-0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1352458513494489","article-title":"Cytomegalovirus seropositivity is negatively associated with multiple sclerosis","volume":"20","author":"Sundqvist","year":"2014","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12839-BIB0026|ane12839-cit-0026","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.molmed.2014.11.002","article-title":"Cytomegalovirus: a culprit or protector in multiple sclerosis?","volume":"21","author":"Vanheusden","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1111\/ane.12839-BIB0027|ane12839-cit-0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.msard.2016.07.002","article-title":"A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - rationale and design","volume":"9","author":"Curtin","year":"2016","journal-title":"Mult Scler Relat Disord"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12839","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12839\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:50:38Z","timestamp":1671522638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1111\/ane.12839","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10,25]]}}}